Data and Analytics

Data needs vary from brand to brand. It’s critical for pharma brands to employ customized copay analytics strategies for their patient access programs.

How can you build more transparency in your pharmacy contract? We lay out five critical strategies to ensure you have control and oversight over your program.

In this Truveris webinar, we join Mployer Advisor to tackle pharmacy benefits 101. What should payers know about PBMs as they plan for 2023?

The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

How can you inject more transparency into your pharmacy plan? Watch the recording of our webinar.

Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.

Watch Truveris’ exclusive Human Resources round table, originally recorded on June 8th, 2022.

Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?

Truveris covers exactly how leading employer groups and their brokers are implementing copay maximizers and accumulators.

As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?

With so much importance placed on the launch of a new drug, how should pharma brands ensure a successful launch?  

How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.

Truveris announces the launch of oneRx, the only drug price transparency solution that helps members navigate their pharmacy benefits.

After you procure a strong PBM contract, make sure your members are engaging with the plan productively.

See how Truveris has helped employers of all sizes procure their pharmacy benefits.

By framing your pharmacy benefits strategy around these three pillars, you’ll construct a more cost-effective, accessible pharmacy program.

With Delta and Omicron, the COVID-19 pandemic carries on. How are these variants impacting pharma brands?

Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?

What is member-centricity? Why should plan sponsors and brokers strive to reimagine their pharmacy program with members in mind?

Read Truveris’ data report on the impact of COVID-19 on pharma, specifically prescribing and claims numbers for branded drugs.

Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?

What is the future of the PBM landscape? Listen to Truveris CEO, Nanette Oddo, opine on the shifts she’s seeing in the pharmacy ecosystem.

Get up to speed on all the industry-speak and confusing jargon that surrounds the work of PBMs.

Your entire access strategy hinges on your patient abandonment rate. Is your patient abandonment rate calculated correctly?

While the goals of every copay program vary, the top 5 essential ROI metrics to track its success stay the same.